DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX): $4.53

0.21 (+4.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DRRX POWR Grades

  • Sentiment is the dimension where DRRX ranks best; there it ranks ahead of 83.24% of US stocks.
  • DRRX's strongest trending metric is Stability; it's been moving down over the last 177 days.
  • DRRX's current lowest rank is in the Momentum metric (where it is better than 10.23% of US stocks).

DRRX Stock Summary

  • Of note is the ratio of DURECT CORP's sales and general administrative expense to its total operating expenses; just 13.98% of US stocks have a lower such ratio.
  • DRRX's price/sales ratio is 5.59; that's higher than the P/S ratio of 81.43% of US stocks.
  • The volatility of DURECT CORP's share price is greater than that of 98.54% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are DARE, PULM, PRQR, VCNX, and MEIP.
  • Visit DRRX's SEC page to see the company's official filings. To visit the company's web site, go to www.durect.com.

DRRX Valuation Summary

  • DRRX's EV/EBIT ratio is -2.7; this is 140.91% lower than that of the median Healthcare stock.
  • Over the past 243 months, DRRX's EV/EBIT ratio has gone down 1.1.

Below are key valuation metrics over time for DRRX.

Stock Date P/S P/B P/E EV/EBIT
DRRX 2023-03-24 5.6 4.3 -3.0 -2.7
DRRX 2023-03-23 5.8 4.4 -3.1 -2.8
DRRX 2023-03-22 5.8 4.5 -3.2 -2.8
DRRX 2023-03-21 5.9 4.5 -3.2 -2.8
DRRX 2023-03-20 5.9 4.6 -3.2 -2.8
DRRX 2023-03-17 5.9 4.6 -3.2 -2.8

DRRX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 32.71%.
  • Its 4 year net cashflow from operations growth rate is now at 112.96%.
  • The 2 year revenue growth rate now stands at -51.5%.
Over the past 49 months, DRRX's revenue has gone down $11,210,000.

The table below shows DRRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 23.265 -28.98 -31.872
2022-06-30 13.453 -34.11 -39.378
2022-03-31 13.68 -32.161 -36.973
2021-12-31 13.977 -37.311 -36.265
2021-09-30 5.489 -34.58 -24.897
2021-06-30 6.007 -35.905 -24.252

DRRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DRRX has a Quality Grade of C, ranking ahead of 38.99% of graded US stocks.
  • DRRX's asset turnover comes in at 0.065 -- ranking 305th of 680 Pharmaceutical Products stocks.
  • CCXI, LCI, and BHC are the stocks whose asset turnover ratios are most correlated with DRRX.

The table below shows DRRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.065 1.013 -0.373
2021-03-31 0.353 0.982 0.023
2020-12-31 0.412 0.953 0.031
2020-09-30 0.554 0.889 -0.138
2020-06-30 0.624 0.914 0.013
2020-03-31 0.366 0.850 -0.615

DRRX Price Target

For more insight on analysts targets of DRRX, see our DRRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.50 Average Broker Recommendation 1.33 (Strong Buy)

DRRX Stock Price Chart Interactive Chart >

Price chart for DRRX

DRRX Price/Volume Stats

Current price $4.53 52-week high $9.70
Prev. close $4.32 52-week low $3.16
Day low $4.21 Volume 77,000
Day high $4.59 Avg. volume 89,210
50-day MA $5.24 Dividend yield N/A
200-day MA $5.41 Market Cap 110.92M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

7 Biotech Stocks Sitting in the Sweet Spot

Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | March 24, 2023

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.

Yahoo | March 21, 2023

DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript

DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter 2022 Earnings Call. . I will now turn the conference over to our host, Tim Papp, Chief Financial Officer. Thank you. You may begin. Timothy Papp: Good afternoon, and welcome to DURECT Corporation’s Fourth […]

Yahoo | March 11, 2023

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.

Yahoo | March 9, 2023

Q4 2022 DURECT Corp Earnings Call

Q4 2022 DURECT Corp Earnings Call

Yahoo | March 8, 2023

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -6.21%
3-mo 30.92%
6-mo -23.18%
1-year -25.10%
3-year -70.58%
5-year -78.83%
YTD 30.92%
2022 -64.91%
2021 -52.37%
2020 -45.53%
2019 691.67%
2018 -47.83%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7968 seconds.